Q301--CAREDX Post heart transplant rejection surveillance tests - SOLE SOURCE RFP
Posted
Oct 7, 2026
Oct 12, 2026
Provide the proprietary AlloMap® gene expression profiling and AlloSure® donor-derived cell-free DNA (dd-cfDNA) assays to satisfy this requirement. Services will include a five (5) year IDIQ ordering period contract.
